Literature DB >> 8769705

Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group.

B Simonsson1, G Oberg, M Björeman, M Björkholm, J Carneskog, G Gahrton, R Hast, H Karl, J Lanng-Nielsen, E Löfvenberg, C Malm, I Turesson, A M Udén, L Vilén, O Weis-Bjerrum.   

Abstract

With the rationale that a significant reduction of the malignant clone in CML might prolong time to metamorphosis, intensive treatment was given to patients < or = 55 years. Six months of hydroxyurea and high dose interferon-alpha (IFN-alpha) was followed by one to three courses of intensive chemotherapy. Patients who had a donor were allotransplanted and patients who became Ph-negative in bone marrow were autotransplanted. On 1 May 1995, 160 patients were registered in the study. Fifty-one percent of the patients who received six months IFN-alpha and hydroxyurea had a significant Ph-reduction and 5% became Ph-negative. The corresponding figures after two intensive chemotherapy courses were 47 and 28%, respectively. Twenty-seven of 30 autotransplanted patients have been analysed for Ph. Seventeen have relapsed cytogenetically, while ten are Ph-negative 1-64 + months after ABMT. BMT was performed in 59 patients. The actuarial 6-year survival from diagnosis of all 160 registered patients is 68%, which seems to be better than for age-matched historical controls.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769705

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.

Authors:  Magnus Björkholm; Lotta Ohm; Sandra Eloranta; Asa Derolf; Malin Hultcrantz; Jan Sjöberg; Therese Andersson; Martin Höglund; Johan Richter; Ola Landgren; Sigurdur Y Kristinsson; Paul W Dickman
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

2.  High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study.

Authors:  W Deenik; B van der Holt; G E G Verhoef; A V M B Schattenberg; L F Verdonck; S M G J Daenen; P Zachée; P H M Westveer; W M Smit; S Wittebol; H C Schouten; B Löwenberg; G J Ossenkoppele; J J Cornelissen
Journal:  Ann Hematol       Date:  2006-10-10       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.